Boston, Massachusetts – Feb 17, 2020 – A leading software company called Elucid Bioimaging believes it can. Approximately 1.5 million Americans have a heart attack or stroke each year. They are the two leading causes of death in developed countries around the world, but do we have an opportunity to improve our ability to predict these events? And can we deliver personalized treatment to prevent them?
Boston-based Elucid Bioimaging says they can… and have the numbers to prove it. Their product, vascuCAP, uses machine learning, a form of artificial intelligence, to analyze images (CT scans of arteries) for information that cannot be seen by the human eye. Machine learning allows computers to run simulations with data in real time and learn from each simulation run. This helps the software identify possible issues thousands of times faster than the human eye of even the best trained professional. When their software is used along with modern medical scans, you can find out much more information from that data now than ever before.
To understand how this works, it is important to recognize how heart attacks and strokes occur. The most common cause of these events is a disease known as atherosclerosis, which results in the thickening and hardening of arterial walls due to a buildup of plaque. Plaque is caused by several factors, including heredity, diet, stress, lack of exercise, and smoking. As plaque builds along the artery wall, it can restrict blood flow. Certain plaques have a higher likelihood of breaking away from the artery wall (rupturing), which may cause blood to clot & block the artery altogether. Blood can no longer flow. When this occurs in the coronary artery for blood heading to the heart, it causes a heart attack. For the carotid artery to the brain, a stroke. Physicians commonly use information about how narrow an artery is to determine the likelihood of a heart attack or stroke and make treatment decisions. The problem is that this does not accurately predict whether the plaque will break away from the wall, cause a clot, and block that artery. Current diagnostics are inaccurate over 30% of the time in predicting heart attacks and 45% of the time for strokes, which can be a life or death error. There simply has not been a tool available to determine the type of plaque within the artery & its likelihood to
Elucid Bioimaging realized this issue and spent 10+ years researching & developing a solution. Their product, vascuCAP, is an FDA-cleared software that is being used by physicians across the U.S. and Europe. It works by using machine learning to analyze CT scans of arteries and automatically quantify and classify the type of atherosclerotic plaque. This information, along with key measures of the artery structure, lead to a 95% accuracy in predicting heart attacks and 87% accuracy for strokes. A substantial improvement over today’s methods, and it is only getting better.
An important benefit of vascuCAP is the cost savings experienced by health systems and patients. According to the American College of Cardiology, over 40% of patients sent to the cath lab for a coronary angiogram (an invasive diagnostic) have no obstructive coronary heart disease. The issue is that typical tests to determine risk are not sufficiently accurate. vascuCAP addresses this issue. Its unprecedented accuracy and low cost allows for widespread adoption. Founder and CTO Andrew Buckler says, “There is a real opportunity here to vastly improve the way cardiovascular disease is diagnosed and treated, reducing unnecessary cardiac intervention, supporting better outcomes for patients around the globe, and, importantly in healthcare today, doing so in a cost-effective manner.”
For additional information please contact Elucid Bioimaging by phone (617-329-9487) or
email (email@example.com). You will also find further information on our web site at https://www.elucidbio.com
About Elucid Bioimaging:
What is now Elucid Bioimaging began studies in 2009 with a mission to better understand the underlying cause of heart attacks and strokes: subclinical atherosclerosis. After years of promising studies, Elucid sought to translate these findings into a usable clinical tool to deliver better care and help reduce the number of heart attacks and strokes.
Company Name: Elucid Biomaging
Contact Person: Blake Richards
Email: Send Email
Phone: +1 617-329-9487
Address:2 Park Plaza
Country: United States